Andere Sprachen CervoMed Inc.

Aktien

A3ES01

US15713L1098

CRVO

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:11:31 28.05.2024			% 5 Tage	% 1. Jan.
18,44 ^USD	-1,34 %		-5,86 %	+139,84 %

20.05.	CervoMed ernennt William Elder zum CFO	MT
08.04.	CERVOMED INC. : Canaccord Genuity bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

CervoMed Names William Elder CFO	20.05.
CervoMed to Appoint William Elder as Chief Financial Officer	20.05.
Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M	15.05.
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates	15.05.
CervoMed : Nominating and Corporate Governance Committee Charter	06.05.
CervoMed : Corporate Presentation April 2024	22.04.
CervoMed : Corporate Presentation April 2024	03.04.
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	01.04.
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
CervoMed to Participate in Upcoming Investor Conferences	28.03.
CervoMed Prices $50 Million Equity Sale to Private Investors	28.03.
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors	28.03.
CervoMed Inc. announced that it expects to receive $49.999967 million in funding	28.03.
CervoMed : Shareholder Meeting - Form 8-K	18.03.
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024	05.03.
CervoMed to Participate in the BIO CEO and Investor Conference	21.02.
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board	20.02.
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	12.02.
Cervomed Inc. Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal That Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	12.02.
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CervoMed Inc.

Aktien

A3ES01

US15713L1098

CRVO

Andere Sprachen

Filter